絞り込み

17360

広告

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.

著者 Wagner AJ , Kindler H , Gelderblom H , Schöffski P , Bauer S , Hohenberger P , Kopp HG , Lopez-Martin JA , Peeters M , Reichardt P , Qin A , Nippgen J , Ilaria RL , Rutkowski P
Ann Oncol.2017 Mar 01 ; 28(3):541-546.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (36view , 0users)

Full Text Sources

Medical

Research Materials

This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively).
PMID: 28426120 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード